Diagnostic and predictive role of 64CuCl2 PET / CT in bladder cancer patients eligible for chemotherapy - Diagnostic-predictive role of 64CuCl2 in urothelial tumors

开始日期2021-03-08

申办/合作机构

Ente Ospedaliero Ospedali Galliera

EUCTR2018-004667-30-IT

/ Not yet recruiting临床2期IIT

Diagnostic and clinical value of 64CuCl2 in HGG/DIPG - 64CuCl2 in high grade glioma

开始日期2019-09-16

申办/合作机构

Ente Ospedaliero Ospedali Galliera

EUCTR2019-000744-10-IT

/ Unknown status临床3期

Higher diagnostic accuracy of 64Cu PET/CT compared to standard 18F-choline PET/CT in the detection rate of metastasis from prostate cancer.Phase III multicenter, sponsored, interventional open-label clinical study, with prospective enrollment. - 64CuCl2 PET/CT VS 18F-choline PET/CT in prostate cancer

开始日期2019-06-28

申办/合作机构

A.C.O.M. - Advanced Center Oncology Macerata - Srl

100 项与氯化铜[64Cu] 相关的临床结果

登录后查看更多信息

100 项与氯化铜[64Cu] 相关的转化医学

登录后查看更多信息

100 项与氯化铜[64Cu] 相关的专利（医药）

登录后查看更多信息

项与氯化铜[64Cu] 相关的文献（医药）

2023-01-01·Frontiers in medicine

Modifications in cellular viability, DNA damage and stress responses inflicted in cancer cells by copper-64 ions.

Article

作者: Stan, Miruna ; Niculae, Dana ; Cornoiu, Maria R ; Mustăciosu, Cosmin ; Manda, Gina ; Temelie, Mihaela ; Neagoe, Ionela ; Cocioabă, Diana ; Dinischiotu, Anca ; Leonte, Radu A ; Serban, Radu M ; Chilug, Livia E ; Dobre, Maria ; Niculae, Dragoș A

Due to combined therapeutical emissions, a high linear energy transfer Auger-electrons with the longer ranged β^- particles, ⁶⁴Cu-based radiopharmaceuticals raise particular theragnostic interest in cancer, by joined therapeutic and real-time PET imaging properties. The in vitro study aimed to investigate the biological and molecular background of ⁶⁴CuCl₂ therapy by analyzing the damages and stress responses inflicted in various human normal and tumor cell lines. Colon (HT29 and HCT116) and prostate carcinoma (DU145) cell lines, as well as human normal BJ fibroblasts, were treated up to 72 h with 2-40 MBq/mL ⁶⁴CuCl₂. Radioisotope uptake and retention were assessed, and cell viability/death, DNA damage, oxidative stress, and the expression of 84 stress genes were investigated at various time points after [⁶⁴Cu]CuCl₂ addition. All the investigated cells incorporated ⁶⁴Cu ions similarly, independent of their tumoral or normal status, but their fate after exposure to [⁶⁴Cu]CuCl₂ was cell-dependent. The most striking cytotoxic effects of the radioisotope were registered in colon carcinoma HCT116 cells, for which a substantial decrease in the number of metabolically active cells, and an increased DNA damage and oxidative stress were registered. The stress gene expression study highlighted the activation of both death and repair mechanisms in these cells, related to extrinsic apoptosis, necrosis/necroptosis or autophagy, and cell cycle arrest, nucleotide excision repair, antioxidant, and hypoxic responses, respectively. The in vitro study indicated that 40 MBq/mL [⁶⁴Cu]CuCl₂ delivers a therapeutic effect in human colon carcinoma, but its use is limited by harmful, yet lower effects on normal fibroblasts. The exposure of tumor cells to 20 MBq/mL [⁶⁴Cu]CuCl₂, might be used for a softer approach aiming for a lower radiotoxicity in normal fibroblasts as compared to tumor cells. This radioactive concentration was able to induce a persistent decrease in the number of metabolically active cells, accompanied by DNA damage and oxidative stress, associated with significant changes in stress gene expression in HCT116 colon cancer cells.

2022-11-16·Bioconjugate chemistry

Synergism of ⁶⁴Cu-Labeled RGD with Anti-PD-L1 Immunotherapy for the Long-Acting Antitumor Effect

Article

作者: Zhang, Xianzhong ; Zeng, Xinying ; Zhang, Yiren ; Zhuang, Rongqiang ; Guo, Zhide ; Wu, Xiaoming ; Liu, Jia ; Shi, Changrong ; Wen, Xuejun ; Chen, Xiaoyuan

We put forward a novel targeting-triggering-therapy (TTT) scheme that combines ⁶⁴Cu-based targeted radionuclide therapy (TRT) with programmed death-ligand 1 (PD-L1)-based immunotherapy for enhancing therapeutic efficacy. The α_vβ₃ integrin-targeted ⁶⁴Cu-DOTA-EB-cRGDfK (⁶⁴Cu-DER) was synthesized. Flow cytometry, immunofluorescence staining, and RT-qPCR were performed to verify PD-L1 upregulation after irradiation with ⁶⁴Cu-DER. Positron emission tomography imaging was performed to investigate the prominent tumor retention property of ⁶⁴Cu-DER. In the MC38 tumor model, anti-PD-L1 antibody (αPD-L1 mAb) was delivered in a concurrent or sequential manner after ⁶⁴Cu-DER was injected, followed by the testing of changes in tumor microenvironment (TME). PD-L1 was upregulated in a time- and dose-dependent manner after being induced by ⁶⁴Cu-DER. The combination of ⁶⁴Cu-DER TRT (925 MBq/kg) and αPD-L1 mAb (10 mg/kg) resulted in significant delay in tumor growth and protected against tumor rechallenge. Blockade of PD-L1 at 4 h after ⁶⁴Cu-DER TRT (⁶⁴Cu-DER + αPD-L1 mAb @ 4 h combination group) was able to achieve 100% survival rate, prevent tumor relapse, and evidently prolong the survival of mice. In summary, the combination of ⁶⁴Cu-DER and αPD-L1 mAb in a time-dependent manner could be a promising approach to improve therapeutic efficacy. Understandably, this strategy has the potential to extend the scope of ⁶⁴Cu-based TTT and merits translation into clinical practice for the better management of immune checkpoint blockade immunotherapy.

2022-04-01·Nuclear medicine and molecular imaging

Recent Advances in Cancer Imaging with 64CuCl2 PET/CT

Review

作者: Peng, Fangyu

Copper is required for cancer cell proliferation and tumor angiogenesis. Radioactive copper-64 chloride (⁶⁴CuCl₂) is a useful radiotracer for cancer imaging with position emission tomography (PET) based on increased cellular uptake of copper mediated by human copper transporter 1 (hCtr1) expressed on cancer cell membrane. Significant progress has been made in research of using ⁶⁴CuCl₂ as a radiotracer for cancer imaging with PET. Radiation dosimetry study in humans demonstrated radiation safety of ⁶⁴CuCl₂. Recently, ⁶⁴CuCl₂ was successfully used for PET imaging of prostate cancer, bladder cancer, glioblastoma multiforme (GBM), and non-small cell lung carcinoma in humans. Based on the findings from the preclinical research studies, ⁶⁴CuCl₂ PET/CT also holds potential for diagnostic imaging of human hepatocellular carcinoma (HCC), malignant melanoma, and detection of intracranial metastasis of copper-avid tumors based on low physiological background of radioactive copper uptake in the brain. Copper-64 radionuclide emits both β⁺ and β^- particles, suggesting therapeutic potential of ⁶⁴CuCl₂ for radionuclide cancer therapy of copper-avid tumors. Recent progress in production of therapeutic copper-67 radionuclide invites clinical research in use of theranostic pair of ⁶⁴CuCl₂ and ⁶⁷CuCl₂ for cancer imaging and radionuclide therapy.

项与氯化铜[64Cu] 相关的新闻（医药）

2022-09-05

·PRNewswire

Global $1.31 Bn Prostate Cancer Nuclear Medicine Diagnostics Market to 2028: Opportunities in the Growing Use of Radiopharmaceuticals

DUBLIN, Sept. 5, 2022 /PRNewswire/ -- The "Prostate Cancer Nuclear Medicine Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type, PET Product, and End User" report has been added to ResearchAndMarkets.com's offering. The global prostate cancer nuclear medicine diagnostics market is expected to grow from US$ 720.12 million in 2022 to US$ 1,315.66 million by 2028. It is estimated to grow at a CAGR of 10.6% from 2022 to 2028. Prostate cancer affects the prostate glands in males. Prostate cancer is common cancer following skin cancer in males. Common determinants responsible for prostate cancer are family history, old age, and race. Nuclear medicine is imaging that needs radioactive materials. It is a helpful method to identify and treat prostate cancer and helps radiologists conclude the stage of cancer. In terms of occurrence, prostate cancer (PCa) is the fourth most common cancer across the US. The rising incidences of prostate cancer in the country led to the increased use of nuclear medicines for its treatment. This cancer is more likely to grow in older adults. Thus, the rising cases of prostate cancer offer substantial growth opportunities for the prostate cancer nuclear medicine diagnostics market during the forecast period. Based on type, the prostate cancer nuclear medicine diagnostics market is bifurcated into SPECT and PET. The PET segment held the largest share of the market in 2021 and is anticipated to register the highest CAGR during the forecast period. A positron Emission Tomography (PET) scan is usually the most effective way to restage recurrent prostate cancer. After prostate cancer treatment, PET scanning may be used to determine the effectiveness of the treatment and is now commonly being used to detect biochemically recurrent prostate cancer for restaging. Rising research activities for developing novel imaging agents to improve prostate cancer detection and the development of novel imaging agents to improve prostate cancer detection are key factors driving the growth of nuclear medicine diagnostics. Researchers are conducting several studies to introduce new diagnostic agents for PET with higher efficiency than the existing agents. For instance, in March 2018, a study in The Journal of Nuclear Medicine demonstrated a novel PET agent named Copper-64 Chloride (64CuCl2) to detect prostate cancer. This new imaging agent exhibited a higher detection rate when compared with Fluorine-18-Choline (18F-choline). The adoption of PET as a diagnostic tool is significantly increasing, as it offers higher accuracy to that other diagnostic techniques. Accuracy in diagnosis has a direct impact on decision-making and treatment monitoring processes. Increasing demand for these diagnostic procedures is expected to fuel the growth of the prostate cancer nuclear medicine diagnostics market during the forecast period. Reimbursement policies is expected to further fuel the development of nuclear medicine diagnostics. Several programs such as Medicaid, Medicare, and the Health Insurance programs in the US are expected to create growth opportunities for the market players. For instance, the Centers for Medicare & Medicaid Services (CMS) covers PET services through National Coverage Determination (NCD) which includes tracers necessary for the diagnosis of prostate cancer. Therefore, due to the factors mentioned above, PET is expected to hold the largest market share. Key Market Dynamics Market Drivers Rising Prevalence of Prostate Cancer Surging Demand for Early and Precise Diagnosis of Prostate Cancer Market Restraints High Cost Related to the Prostate Cancer Diagnostics and Treatment Market Opportunities Growing Use of Radiopharmaceuticals in Prostate Cancer Future Trends Increasing Research Activities for Development of Innovative Imaging Agents Company Profiles Blue Earth Diagnostics Limited ImaginAB Curium Jubilant Radiopharma NCM-USA LLC ABX Advanced Biochemical Compounds GmbH Telix Pharmaceuticals Ltd. Novartis AG Theragonostics Lantheus Medical Imaging Inc. For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

诊断试剂

100 项与氯化铜[64Cu] 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
腺癌	临床2期	意大利	Ente Ospedaliero Ospedali Galliera	2021-03-08
膀胱癌	临床2期	意大利	Ente Ospedaliero Ospedali Galliera	2021-03-08
肌肉疾患	临床2期	意大利	Ente Ospedaliero Ospedali Galliera	2021-03-08
尿路上皮癌	临床2期	意大利	Ente Ospedaliero Ospedali Galliera	2021-03-08
弥漫内生性脑桥神经胶质瘤	临床2期	意大利	Ente Ospedaliero Ospedali Galliera	2019-09-16
前列腺癌	临床2期	意大利	Ente Ospedaliero Ospedali Galliera	2015-11-12

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


EANM2024	临床1期	复发性胶质母细胞瘤 64CuCl2 PET/CT scan	21	64CuCl2	遞蓋築獵膚製獵願襯築(餘選構艱製選鬱鬱餘範) = 築構壓齋築繭膚網構糧憲夢廠網鬱觸選鏇齋醖 (遞範壓醖壓鏇顧顧鏇夢 ) 更多	积极	2024-09-27
EANM2021	N/A	高级别胶质瘤	10	64CuCl2	艱艱餘餘廠簾膚獵餘願(範淵觸遞觸醖衊網淵襯) = The PET-based volumes were more similar to the T1- than to the FLAIR-derived ones (median of 2.95, 6.31, and 2,67 ml for T1, FLAIR, and PET, respectively) 製製鏇觸鑰廠製壓廠範 (顧餘艱鬱網蓋膚廠觸鬱 ) 更多	-	2021-09-24